Tag: AgeX

As a millennial with limited orientation abilities but expertise with digital tools, I used Google Maps to find the venue, fearing that I would have no data and would get lost in Berlin, only to find out that I was only a couple of meters away from to the venue entrance. The Undoing Aging 2019...

Last Wednesday, I landed in Berlin, Germany at around 12:30. About an hour later, I was briefly in Cafè Alex, right next to the tapering TV Tower, where I met some of my colleagues from LEAF—some of whom I had never seen in person before—as well as other volunteers and members of HEALES, our friend...

Earlier this year, we hosted the Ending Age-Related Diseases 2018 conference at the Cooper Union in New York City. This conference was designed to bring together the best in the aging research and biotech investment worlds and saw a range of industry experts sharing their insights. Dr. Oliver Medvedik, LEAF vice president and Director of...

Yet another important investment in the field of regenerative medicine against aging demonstrates the increasing interest of investors in this industry; on August 2, BioTime, Inc. announced that Juvenescence Limited will buy 14.4 million of its subsidiary AgeX Therapeutics' shares for a total of $43.2 million—50% to be paid in cash and 50% with a...

We were interested to learn that Juvenescence Limited, a biotech and development company involved in the development of therapies that target the aging processes, has successfully raised $50 million in a series A financing round. Jim Mellon, the chairman of Juvenescence Limited, said, "We are delighted with the progress we have made and the faith...